Nanjing Pharmaceutical

Nanjing Pharmaceutical Co., Ltd. was established in 1951 and listed on the Shanghai Stock Exchange in 1996. It is one of the earlier listed companies in China's pharmaceutical distribution industry and has now developed into a cross-regional, network-based group enterprise. At the end of 2014, the company introduced Walgreens Boots Alliance, a Fortune 500 company and a global leader in pharmaceutical commerce (which merged with Walgreens at the end of the same year to form a world-class pharmacy-led healthcare enterprise), as a strategic investor, actively exploring mixed-ownership reform (currently state-owned shares account for 44.18%, foreign shares account for 11.04%). The company focuses on the development of the health industry, with pharmaceutical wholesale and retail as its main businesses. It is a regional pharmaceutical commercial leader in China’s pharmaceutical distribution industry. The company currently has around 80 subsidiaries, with market networks covering Jiangsu, Anhui, Fujian, Hubei, and parts of Southwest China (ranking high in market share in Jiangsu, Anhui, Fujian, and Hubei provinces). Its business covers nearly 70 cities, accumulating rich experience, resources, and brand recognition in regional pharmaceutical commerce operations, with annual revenue exceeding 45 billion yuan. In 2021, it ranked seventh in scale nationwide in the industry and 273rd in the Fortune China 500 (based on 2020 revenue).The company has been awarded titles such as National Pharmaceutical Distribution Innovation Demonstration Enterprise and successfully selected as one of the first batch of "National Supply Chain Innovation and Application Demonstration Enterprises." It is one of the leading enterprises in Nanjing's new pharmaceuticals and life health industry chain. As a pioneer in pharmaceutical services in China, the company has been following national healthcare reform policies over the years, striving to explore and practice innovative pharmaceutical service management, forming mature models such as independently operated hospital drug warehouses, zero-inventory drug warehouse management, and SCM drug supply chain platforms. Subsidiaries under the company leverage their advantages in traditional Chinese medicine (TCM) pharmaceutical services, transitioning traditional TCM decoction and compounding services, nourishing paste preparation services, and IT information technology to an "Internet + TCM pharmaceutical services" operation model. Through intelligent TCM decoction bases, they provide characteristic TCM health services. The number of hospital clients for TCM pharmaceutical services in the Nanjing region continues to increase, expanding regional influence and social impact. The company’s retail business consists of two parts: social retail pharmacies and specialty drugstores, with nearly 600 owned retail stores. There are about 430 social retail pharmacies, over 90% of which have designated medical insurance qualifications, including six century-old pharmacies, and nine regional brand chain institutions like Baixin Pharmacy. There are nearly 170 specialty drugstores, including self-operated DTP pharmacies and professional pharmacies inside or near hospitals, providing specialized services and actively deploying in the external prescription flow market from medical institutions. Guided by customer health needs, the company strengthens pharmaceutical service levels, effectively manages members and services, explores multi-model pharmaceutical retail businesses, and builds the "Nanjing Pharmaceutical Health Management" retail brand.